PTO/SB/29 (12/97)

Approved for use through 09/30/00. OMB 0651-0032 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

EL 451 596 906 US

UTILITY c PATENT APPLICATION TRANSMITTAL for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 9196-019-999 Total Pages First Named Inventor or Application Identifier Jean-Louis Dasseux

Express Mail Label No.

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.

Assistant Commissioner for ADDRESS TO: Box Patent Application Washington, DC 20231 6. ☐ Microfiche Computer Program (Appendix)

a.

Computer Readable Copy

1. X Fee Transmittal Form Submit an original, and a duplicate for fee processing) 2. X Specification [Total Pages 140]

(preferred arrangement set forth below) -Descriptive title of the Invention

-Cross Reference to Related Applications -Statement Regarding Fed sponsored R&D -Reference to Microfiche Appendix -Background of the Invention

-Brief Summary of the Invention -Brief Description of the Drawings (if filed)

-Detailed Description of the Invention (including drawings, if filed) :0 -Claim(s)

-Abstract of the Disclosure Drawing(s) (35 USC 113)

[Total Sheets 11] [Total Sheets 2]

4. Oath or Declaration ila. □ Newly executed (original or copy)

 ⊠ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17 completed)

Lff [Note Box 5 below]

Customer Number: 24341

i. DELETION OF INVENTORS(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).

Incorporation By Reference (useable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby

b. R. Paper Copy (identical to computer copy) c.

Statement verifying identity of above copies

7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)

ACCOMPANYING APPLICATION PARTS 8.

Assignment Papers (cover sheet & document(s))

9 II 37 CER 3 73/h) Statement II Power of Attorney (when there is an assignee)

10.

English Translation Document (if applicable) Copies of IDS

11. □ Information Disclosure Statement (IDS)/PTO-1449 12.

■ Preliminary Amendment

13.

■ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)

14.

Applicant claims Small Entity status, see 37 C.F.R.

§ 1 27

15. □ Certified Copy of Priority Document(s) (if foreign priority is claimed)

16 m Other:

incorporated by reference therein. 17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information: ■ Continuation □ Divisional

of prior application No: 09/465,719 filed December 17, 1999. ☐ Continuation-in-part (CIP)

18. CORRESPONDENCE ADDRESS

ladalaladadladadadladlad (Insert Customer No. or Attach bar code label here) or Correspondence address below

NAME **ADDRESS** CITY STATE ZIP CODE COUNTRY TELEPHONE

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the answer of time you are regulate to complete this form about to sent to the Chief Information Officer, Pastern and Trasfernak Office.

Application, Weshington, DC 202315.00 PEES OR COMPLETED POINTS OF this PADDIESS. SEED TO: Assessmir Commissioner for Festins; too Festivat.

Express Mail No.: EL 451 596 906 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| Prior application: | Examiner Russell, J. | | | | | |
|--------------------|----------------------|--|--|--|--|--|
| ** | | | | | | |
| | Art Unit 1653 | | | | | |

Assistant Commissioner for Patents Box PATENT APPLICATION Washington, D.C. 20231

Sir:

100

This is a request for filing a continuation \square divisional application under 37 CFR § 1.53(b), of pending prior Application Serial No. 09/465,719 filed on December 17, 1999.

f <u>Jean-Louis Dasseux, Renate Sekul, Klaus Buttner, Isabelle Cornut and Gunter Metz</u> (inventor(s) currently of record in prior application)

APOLIPOPROTEIN A-I AGONISTS AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS (title of invention)

The filing fee is calculated below:

PATENT APPLICATION FEE VALUE

| TYPE | NO. FILED | LESS | EXTRA | EXTRA RATE | FEE | |
|---|-----------|------|-------|--------------|-----|--------|
| Total Claims | 14 | -20 | 0 | \$18.00 each | \$ | 0.00 |
| Independent | 2 | -3 | 0 | \$80.00 each | \$ | 0.00 |
| Basic Fee | | | | | | 710.00 |
| Multiple Dependency Fee If Applicable (\$270.00) | | | | | \$ | 270.00 |
| Total | | | | | \$ | 980.00 |
| 50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern Total Filing Fee | | | | | | 490.00 |
| | | | | | | 490.00 |

- Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.
- Amend the specification by inserting before the first line the following sentence: This is a continuation of Application Serial No. 09/465,719, filed December 17, 1999.
- 4a. □ Transfer the drawings from the prior application to this application and abandon the prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.

- 4b New formal drawings are enclosed. 4c. Ø Informal drawings are enclosed. 5a. Priority of application no. filed on in is claimed under 35 U.S.C. §119. 5b. The certified copy has been filed in prior application no., filed. 6. 53 The prior application is assigned of record to Esperion Therapeutics, Inc. 7a. The Power of Attorney appears in the original papers in the prior application no., filed. 7b. Since the Power of Attorney does not appear in the original papers, a \boxtimes copy of the Power in prior Application Serial No. 09/465,719, filed December 17, 1999 is enclosed.
- 8. In this application contains nucleic acid and/or amino acid sequences required to be disclosed in a Sequence Listing under 37 CFR §§1.821-1.825. It is requested that the Sequence Listing in computer readable form from prior Application Serial No.09/465,719, filed on December 17, 1999 be made a part of the present application as provided for by 37 C.F.R. §1.821(e). The sequences disclosed therein are the same as the sequences disclosed in this application. A copy of the paper Sequence Listing from Application Serial No. 09/465,719 is enclosed.
- The undersigned states, under 37 C.F.R. §1.821(f), that the content of the enclosed paper Sequence Listing from Application Serial No. 09/465,719 is the same as the content of the computer readable form submitted in Application Serial No. 09/465,719.
- Additional enclosures or instructions. Please enter the Preliminary Amendment canceling Claims 1, 16-18, 25, 33, 40 and 50 prior to calculating the fee.

Respectfully submitted.

Date: May 25, 2001

Rahul Pathak (Reg. No.)

For: Laura A. Coruzzi (Reg. No. 30,742)
PENNIE & EDMONDS LLP
1155 Avenue of the Americas

New York, N.Y. 10036-2711 (212) 790-9090